Therefore in order to have a potent anti-tumor effect, a thorough determination of the genetic status [22,25,26] and a personalized combination therapy with other inhibitors of the Raf/MEK/ERK and PI3K/AKT signaling pathways are needed. This evidence concerns the gene RAF1 and neoplasm.